Autoimmunity Biologic Solutions, Inc.
Autoimmunity Biologic Solutions, Inc. (Autoimmunity BioSolutions, ABS), based in Galveston, Texas, is currently developing a combined diagnostic and therapeutic for the treatment of multiple sclerosis (MS). ABS will be also deploying its therapeutic platform for autoimmune diseases and other diseases (e.g., cancers) that can be addressed by modulation of patients' immune system.
The Company's platform technology is based on research conducted at the University of Texas Medical Branch (UTMB), Galveston, Texas. The company has received funding from UTMB and has been awarded two Phase l grants (an STTR and an SBIR) from the National Institute of Health to pursue the pre-clinical development of its MS program.